Sarepta Therapeutics Inc. | Small-cap | Healthcare
$17.32
-5.04%
| Sarepta Therapeutics Stock Comparison:
Sarepta Therapeutics vs VertexSarepta Therapeutics vs RegeneronSarepta Therapeutics vs Blueprint MedicinesSarepta Therapeutics vs Roivant SciencesSarepta Therapeutics vs Bio-TechneSarepta Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 1.9B
Gross Profit 1.6B 83.22%
Operating Income 218.1M 11.47%
Net Income 235.2M 12.37%
EPS (Diluted) $2.34

Balance Sheet Metrics

Total Assets 4.0B
Total Liabilities 2.4B
Shareholders Equity 1.5B
Debt to Equity 1.59

Cash Flow Metrics

Operating Cash Flow -927.0K
Free Cash Flow -352.7M

Revenue & Profitability Trend

Sarepta Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue1.9B1.2B933.0M701.9M540.1M
Cost of Goods Sold319.1M150.3M140.0M97.0M63.4M
Gross Profit1.6B1.1B793.0M604.8M476.7M
Operating Expenses1.4B1.4B1.3B1.1B1.0B
Operating Income218.1M-267.8M-536.2M-449.7M-564.2M
Pre-tax Income260.8M-520.1M-690.0M-418.9M-553.1M
Income Tax25.5M15.9M13.5M-168.0K1.1M
Net Income235.2M-536.0M-703.5M-418.8M-554.1M
EPS (Diluted)$2.34-$5.80-$8.03-$5.15-$7.11

Income Statement Trend

Sarepta Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets3.1B2.6B2.6B2.6B2.5B
Non-Current Assets889.7M685.2M570.5M543.9M499.5M
Total Assets4.0B3.3B3.1B3.1B3.0B
Liabilities
Current Liabilities731.7M653.7M619.6M452.7M416.0M
Non-Current Liabilities1.7B1.8B2.1B1.8B1.8B
Total Liabilities2.4B2.4B2.7B2.2B2.2B
Equity
Total Shareholders Equity1.5B859.3M385.0M928.0M761.8M

Balance Sheet Composition

Sarepta Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income235.2M-536.0M-703.5M-418.8M-554.1M
Operating Cash Flow-927.0K-887.0M-455.4M-458.9M94.6M
Investing Activities
Capital Expenditures-137.0M-76.1M-30.8M-38.5M-82.2M
Investing Cash Flow765.6M-154.6M-1.0B497.7M-121.7M
Financing Activities
Dividends Paid-----
Financing Cash Flow-68.0K-6.9M303.5M540.8M598.4M
Free Cash Flow-352.7M-588.3M-357.6M-484.0M25.3M

Cash Flow Trend

Sarepta Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 19.98
Forward P/E 1.66
Price to Book 1.63
Price to Sales 0.84
PEG Ratio 1.66

Profitability Ratios

Profit Margin -11.12%
Operating Margin -40.33%
Return on Equity -23.61%
Return on Assets -2.19%

Financial Health

Current Ratio 4.02
Debt to Equity 118.73
Beta 0.60

Per Share Data

EPS (TTM) -$2.64
Book Value per Share $11.63
Revenue per Share $23.28

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
srpt1.9B19.981.63-23.61%-11.12%118.73
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.